|
Home:
Web Guide 2: Alan
P Venook, MD: Select references
Selected references
Borner MM et al. Phase II study of capecitabine and oxaliplatin
in first- and second-line treatment of advanced or metastatic colorectal
cancer. J Clin Oncol 2002;20(7):1759-66. Abstract
Coppola FS et al. A phase III randomized trial (COLON-OXALAD)
of adjuvant therapy for very high risk colon cancer (CC) patients
(pts) with oxaliplatin (OXA) ± bolus 5-fluorouracil (5- FU)/folinic
acid (FA): A toxicity report. Proc ASCO 2002;Abstract
656.
de Gramont A et al. Oxaliplatin/5-FU/LV in adjuvant colon
cancer: Safety results of the international randomized MOSAIC trial.
Proc ASCO 2002;Abstract
525.
Goldberg RM et al. N9741: Oxaliplatin (oxal) or CPT-11
+ 5-fluorouracil (5-FU)/leucovorin (LV) or oxal + CPT-11 in advanced
colorectal cancer (CRC). Initial toxicity and response data from
a GI Intergroup study. Proc ASCO 2002;Abstract
511.
Jordan K et al. Randomized phase II trial of capecitabine
plus irinotecan vs capecitabine plus oxaliplatin as first-line therapy
in advanced colorectal cancer (ACRC): Results of an interim analysis.
Proc ASCO 2002;Abstract
2225.
Rothenberg ML et al. Mortality associated with irinotecan
plus bolus fluorouracil/leucovorin: Summary findings of an independent
panel. J Clin Oncol 19:3801-7. Abstract
Sandberg JA et al. Pharmacokinetics and tolerability of
an antiangiogenic ribozyme (ANGIOZYME) in healthy volunteers.
Clin Pharmacol 2000;40(12 Pt 2):1462-9. Abstract
Sarela AI et al. Non-operative management of the primary
tumour in patients with incurable stage IV colorectal cancer.
Br J Surg 2001;88(10):1352-6. Abstract
Shields AF et al. A phase II trial of oxaliplatin and
capecitabine in patients with advanced colorectal cancer.
Proc ASCO 2002;Abstract
568.
Tabernero J et al. Capecitabine and oxaliplatin in combination
(Xelox) as first-line therapy for patients (pts) with metastatic
colorectal cancer (MCRC): Results of an international multicenter
phase II trial. Proc ASCO 2002;Abstract
531.
Twelves C. Capecitabine as first-line treatment in colorectal
cancer. Pooled data from two large, phase III trials. Eur
J Cancer 2002;38 Suppl 2:15-20. Abstract
Twelves C et al. Capecitabine (Xeloda) improves medical
resource use compared with 5-fluorouracil plus leucovorin in a phase
III trial conducted in patients with advanced colorectal carcinoma.
Eur J Cancer 2001;37(5):597-604. Abstract
Weng DE, Usman N. Angiozyme: A novel angiogenesis inhibitor.
Curr Oncol Rep 2001;3(2):141-6. Abstract
|
